Effect of Guanxinning Tablet on Coronary Microcirculation After Primary Percutaneous Coronary Int… (NCT07621107) | Clinical Trial Compass
Not Yet RecruitingPhase 2
Effect of Guanxinning Tablet on Coronary Microcirculation After Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction
70 participantsStarted 2026-06-01
Plain-language summary
①Research objective: In a small sample population, through the pre - experimental method, explore and evaluate the effect of Guanxinning tablets on the coronary microcirculation after primary percutaneous coronary intervention (PPCI) in patients with acute ST - segment elevation myocardial infarction (STEMI), with the change in the percentage of intramyocardial hemorrhage (IMH) in ventricular mass measured by cardiac magnetic resonance (CMR) imaging as the primary endpoint.
②Research significance: The research results of this project will provide preliminary theoretical basis and methodological support for the formal randomized controlled study on evaluating the effect of Guanxinning tablets on the coronary microcirculation after PPCI in STEMI patients. It will offer new ideas for the long - term clinical treatment of STEMI patients after PPCI, and provide important theoretical support for expanding the clinical indications of Guanxinning tablets and exploring the reasons for its improvement of cardiovascular outcomes.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age between 18 and 80 years (gender is not restricted).
* STEMI diagnosed for the first time and with an onset time within 12 hours. (According to the "Chinese Guidelines for the Diagnosis and Treatment of Acute ST - Segment Elevation Myocardial Infarction 2019" and the fourth - edition "Global Definition of Myocardial Infarction" criteria, myocardial infarction refers to acute myocardial injury \[serum cardiac troponin (cTn) increases and/or decreases, and at least once is higher than the upper limit of the normal value (the 99th percentile of the upper limit of the reference value)\], along with clinical evidence of acute myocardial ischemia, including: (1) Symptoms of acute myocardial ischemia; (2) New ischemic electrocardiogram changes; (3) New pathological Q - wave; (4) New imaging evidence of viable myocardial loss or abnormal wall segmental motion; (5) Coronary artery thrombosis confirmed by coronary angiography, intracavitary imaging examination, or autopsy.)
* Successfully received PPCI treatment (assessed by visual inspection or quantitative coronary angiography, with residual stenosis of the target lesion \< 20% after stent implantation or \< 50% after simple balloon dilation, and forward TIMI blood flow ≥ grade 2).
* Signed a written informed consent form.
Exclusion Criteria:
* Cardiogenic shock with poor response to vasoactive drugs; or uncontrolled acute left - heart failure or pulmonary edema; uncontrolled malignant arrhythmia.
* LVEF \…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is testing a tablet called Guanxinning, which is a traditional Chinese medicine, after a heart attack treated with emergency stenting — is this something you think could be relevant to my situation, and what do you already know about how this kind of treatment works on tiny blood vessels in the heart?
2The trial is specifically measuring something called IMH volume, which seems related to bleeding or injury inside the heart muscle after a heart attack — can you explain what that means for my recovery, and why it might matter whether a treatment reduces it?
3Since this trial is Phase 2 and hasn't started recruiting yet, it means there's still limited safety and effectiveness data on Guanxinning in this specific use — given that, would you recommend I consider standard post-heart attack care first, or do you think joining a trial like this could be worth exploring once it opens?
4This study focuses on coronary microvascular dysfunction after a STEMI — is that something I should be tested or monitored for as part of my own care, regardless of whether I ever participate in this trial?
5Because the trial hasn't started recruiting yet, what would the process look like if I wanted to be considered for it down the road, and are there other ongoing trials or treatments targeting microvascular problems after a heart attack that might be available to me sooner?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.